Custom Peptide, Neoantigen Peptide

• Certification: ISO
• Storage Method: Normal
• Extraction Process: Chemical
• Application: Cosmetics, Food, Health Care Products, Medicine
• State: Powder
• Extract Source: Cow
• Model NO.: HJYY
• Transport Package: 5kg/Bag
• Specification: 5kg/Bag
• Trademark: HD
• Origin: China
• HS Code: 2937190099
• Production Capacity: 10000000/Kg

Product Description

Custom peptide is used for Personalized Treatment of Tumors - Introduction of neoantigen Peptide Project.

Project category: Innovative drugs for personalized treatment of tumors (make chemotherapy history!)

The concept of neoantigen: Proteins with specific amino acid sequence variations produced by cancer cells based on genetic variations are called "neoantigen". Neoantigen is the key to "cancer vaccines", it refers to a new type of antigen caused by factors such as gene mutation, DNA damage, or viral infection, etc. These antigens only exist on the surface of cancer cells rather than normal cells. Therefore, they have become good targets for identifying and attacking cancer cells.
The direction of application: neoantigen peptide has special value in immune checkpoint inhibitor therapy, adoptive T cell therapy, and the development and application of therapeutic tumor vaccines, etc. They bring new hope for precise treatment of malignant tumor and become one of the "cure potential" anti cancer black technologies. Tumor neoantigen has high specificity and targeting. According to the treatment plan, there will be a personalized and precise treatment situation of "one person, one medicine". Therefore, neoantigen is the most ideal target for tumor immunotherapywith broad market prospects and clinical application value.
Project progress: The neoantigen peptide developed by our company has been applied to the research and development of the national Class I innovative drug "XXX for injection" (the first in China), and was approved by the China Food and Drug Administration and the US FDA to enter the Phase I clinical trial on April 7 and August 31, 2023, respectively. The corresponding indications are: patients with high recurrence risk after radical resection of solid tumors, including Phase I/II/III cholangiocarcinoma and pancreatic cancer; Phase II/III esophageal cancer and hepatocellular carcinoma; Phase III colon cancer, gastric cancer, and melanoma.
 

 

Our Advantages

• GMP certified injection and API manufacturing facility.
• High-tech pharmaceutical enterprises with provincial biomedicine R&D center.
• More than 20 years experience.
• High quality standard adopted as the reference of national quality standard.

Company Profile